AtriCure price target raised to $58 from $57 at BTIG

BTIG raised the firm’s price target on AtriCure (ATRC) to $58 from $57 and keeps a Buy rating on the shares after the company’s Investor Day. The firm sees the company’s new products and expansion to power low-teens sales CAGR and greater profitability into 2028, with acceleration in growth rates beyond, the analyst tells investors in a research note.